For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 176,065 | |||
| General and administrative | 60,091 | |||
| Acquired in-process research and development | 5,000 | |||
| Total operating expenses | 241,156 | |||
| Loss from operations | -241,156 | |||
| Interest income | 8,344 | |||
| Interest expense | 3,219 | |||
| Other expense, net | -767 | |||
| Total other income | 4,358 | |||
| Net loss before income taxes | -236,798 | |||
| Provision for income taxes | 130 | |||
| Net loss | -236,928 | |||
| Unrealized gain (loss) on marketable securities | -62 | |||
| Comprehensive loss | -236,990 | |||
| Basic EPS | -1.45 | |||
| Diluted EPS | -1.45 | |||
| Basic Average Shares | 163,391,000 | |||
| Diluted Average Shares | 163,391,000 | |||
Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NMRA)